Secretory carcinoma of breast demonstrates nuclear or cytoplasmic expression in p63 immunohistochemistry

International Journal of Surgical Pathology

Volumn 20, Issue 4, 2012, Pages 367-372

  Choi, Junjeong ^a   Kim, Dokyung ^b   Koo, Ja Seung ^c  

^a Yonsei University Wonju   (South Korea)

^b Ajou University Medical CentSuwon   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

breast; p63; secretory carcinoma

Indexed keywords

PROTEIN MDM2; PROTEIN P53; PROTEIN P63; SMOOTH MUSCLE ACTIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST SECRETORY CARCINOMA; CLINICAL ARTICLE; CYTOPLASM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MYOEPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84863929836     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896912440506     Document Type: Article

References (26)

1. Tavassoli F, Devilee P World Health Organization Classification of Tumors Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press ; 2003:
2. Tavassoli FA, Norris HJ. Secretory carcinoma of the breast. Cancer. 1980 ; 45: 2404-2413 (Pubitemid 10109133)
3. Lae M, Freneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol. 2009 ; 22: 291-298
4. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002 ; 2: 367-376 (Pubitemid 41039103)
5. Levrero M, De Laurenzi V, Costanzo A, Gong J, Melino G, Wang JY. Structure, function and regulation of p63 and p73. Cell Death Differ. 1999 ; 6: 1146-1153 (Pubitemid 30047890)
6. Patturajan M, Nomoto S, Sommer M, et al. DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell. 2002 ; 1: 369-379 (Pubitemid 41039138)
7. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998 ; 2: 305-316 (Pubitemid 128379271)
8. Dietz S, Rother K, Bamberger C, Schmale H, Mossner J, Engeland K. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73. FEBS Lett. 2002 ; 525: 93-99
9. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002 ; 416: 560-564 (Pubitemid 34288861)
10. Urist M, Prives C. p53 leans on its siblings. Cancer Cell. 2002 ; 1: 311-313 (Pubitemid 41039132)
11. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002 ; 8: 494-501 (Pubitemid 34193969)
12. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001 ; 58: 619-624 (Pubitemid 32904513)
13. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001 ; 116: 823-830 (Pubitemid 33108152)
14. Bratthauer GL, Saenger JS, Strauss BL. Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation. Histopathology. 2005 ; 47: 611-616 (Pubitemid 41775184)
15. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 ; 28: 2784-2795
16. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 ; 25: 118-145 (Pubitemid 350003059)
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 ; 19: 403-410
18. Cutler SJ, Black MM, Mork T, Harvei S, Freeman C. Further observations on prognostic factors in cancer of the female breast. Cancer. 1969 ; 24: 653-667
19. Werling RW, Hwang H, Yaziji H, Gown AM. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol. 2003 ; 27: 82-90 (Pubitemid 36014901)
20. Stefanou D, Batistatou A, Nonni A, Arkoumani E, Agnantis NJ. p63 expression in benign and malignant breast lesions. Histol Histopathol. 2004 ; 19: 465-471 (Pubitemid 38450633)
21. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006 ; 208: 495-506 (Pubitemid 43329336)
22. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol. 2000 ; 24: 197-202 (Pubitemid 30078708)
23. Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol. 2004 ; 28: 1506-1512 (Pubitemid 39425518)
24. Gisselsson D, Palsson E, Hoglund M, et al. Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer. 2002 ; 33: 133-140 (Pubitemid 34052494)
25. Kadakia M, Slader C, Berberich SJ. Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol. 2001 ; 20: 321-330 (Pubitemid 32692435)
26. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem. 2002 ; 277: 2674-2681 (Pubitemid 34953294)